|
Fleischmann R et al. – Review article describes the results of up to 100 weeks of treatment with certolizumab pegol (CZP; a PEGylated Fab´ with specificity for human TNF-α)with an emphasis on functional outcomes.
- * The clinically meaningful improvements in HRQoL, HAQ-DI, FAS, PAAP, work and household productivity were reported with the use of CZP plus MTX
-
- * CZP plus MTX either at 200 mg or 400 mg every 2 wks was superior to MTX plus placebo in improvements in each of these areas
-
- * Improvements were seen rapidly with benefit persisting for a minimum of 100 wks
-
- * There was no numerical or statistical difference between 200 or 400 mg CZP each 2 wks in any of the outcomes reported
-
- * Lower dose was just as effective as the higher dose
- Thus the approved dose of CZP in the US is:
- 200 mg subcutaneously each 2 wks, or
- 400 mg subcutaneously each month (total of 400 mg per mo) after a loading dose of 400 mg on wks 0, 2 and 4
http://dovepress.com/the-clinical-efficacy-and-safety-of-certolizumab-pegol-czp-in-the-trea-peer-reviewed-article
| |